Kintara rises as FDA grants orphan drug tag to its brain cancer drug

TuHURA Biosciences

15/12/2022 14:40

** Kintara Therapeutics Inc's shares  KTRA.O  rise 13.7% to
$9.11 in morning trade
    ** Co receives orphan drug designation (ODD) from the U.S.
FDA for its treatment of diffuse intrinsic pontine glioma, a
rare and highly-aggressive childhood brain cancer
    ** ODD programs are for drugs that target rare diseases and
provide the sponsor of the drug with development incentives and
seven-year marketing exclusivity upon FDA approval
    ** The drug is also in a late-stage study for another type
of brain cancer called glioblastoma and has demonstrated
clinical activity against a range of cancers, including central
nervous system, ovarian and other solid tumors - KTRA
    ** Stock down 64.3% YTD
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))